Drug
Cysteamine clinical trials
Also written RP103, PROCYSBI® and Cystagon.
- studies test it
- 26
- open now
- 1
- in phase 3
- 8
- first study started
- 1998
Keep track of what changes. Save the Cysteamine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
24 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 1 |
| 2001 | 1 |
| 2004 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 10
- Phase 3
- 8
- Phase 4
- 1
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 16
Amgen (7) · National Eye Institute (NEI) (2) · Hasanuddin University (1) · Recordati Rare Diseases (1) · China Medical University Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · NovaBiotics Ltd. (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)
Often tested with
Tested in the same studies.
Gamma-Aminobutyric Acid (1) · Deanol (1) · Bakuchiol (1) · Zidovudine (1) · Ceftriaxone (1) · Piperacillin, Tazobactam Drug Combination (1) · Ceftaroline (1) · Amoxicillin (1)
Studies
Open first, then newest update. How each study uses Cysteamine is read from its arms, and is right about nine times in ten.
Testing it · 26
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Cysteamine
- Effectiveness of a Bilayering Serum and Cream Containing GABA, DMAE, Cysteamine, and Bakuchiol for Skin Whitening and Anti-AgingCompletedPhase 2Hasanuddin UniversityNCT07477288Written as Cysteamine
- Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With CystinosisCompletedPhase 3AmgenNCT01744782Written as RP103
- Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial DiseaseCompletedPhase 2AmgenNCT02023866Written as Cysteamine Bitartrate
- Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in CystinosisCompletedPhase 3AmgenNCT01733316Written as RP103
- Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)CompletedPhase 3AmgenNCT01197378Written as Cysteamine Bitartrate Delayed-release Capsules
- A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial DiseaseTerminatedPhase 2AmgenNCT02473445Written as Cysteamine Bitartrate
- Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With CystinosisCompletedPhase 1/2AmgenNCT00872729Written as Cystagon®
- Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With CystinosisCompletedPhase 3AmgenNCT01000961Written as Cystagon® (Cysteamine Bitartrate)
- Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)CompletedPhase 3Recordati Rare DiseasesNCT04125927Written as Mercaptamine
- Cysteamine Compared to Hydroquinone in MelasmaCompletedPhase 3China Medical University HospitalNCT05969587Written as 5% cysteamine cream
- Efficacy and Safety of Topical Cysteamine for Postinflammatory HyperpigmentationStatus unknownNot applicableChang Gung Memorial HospitalNCT05206318Written as Topical Cysteamine
- Cysteamine for AsthmaCompletedPhase 1Children's Hospital Medical Center, CincinnatiNCT03883984Written as Cysteamine Bitartrate
- A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis ExacerbationsCompletedPhase 2NovaBiotics Ltd.NCT03000348Written as Cysteamine
- Cysteamine Therapy for Major Depressive DisorderTerminatedNot applicableIcahn School of Medicine at Mount SinaiNCT00715559Written as cysteamine bitartrate
- Cystagon to Treat Infantile Neuronal Ceroid LipofuscinosisCompletedPhase 4Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT00028262Written as Cystagon
- Efficacy of Topical Cysteamine in Nephropathic CyctinosisCompletedNot applicableThe Eye Center and The Eye Foundation for Research in OphthalmologyNCT02766855Written as Cysteamine
- First Study of Oral Cysteamine in Cystic FibrosisCompletedPhase 1/2University of AberdeenNCT02212431Written as Cysteamine
- Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With CystinosisCompletedNot applicableFDA Office of Orphan Products DevelopmentNCT00010426Written as cysteamine hydrochloride
- An Open Trial of Cysteamine Treatment in SchizophreniaTerminatedNot applicableAugusta UniversityNCT01139125Written as (Cystagon) Cysteamine Bitartrate
See all 26 studies that test Cysteamine →
As the comparator · 1 — what is tested is compared with Cysteamine
Codes
What other systems call Cysteamine · ClinicalTrials.gg INT007287
- MeSH (NLM) D003543CysteamineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5UX2SD1KE2CYSTEAMINEConfirmed FDA, NLM, Wikidata
- RxNorm 3022Confirmed FDA, Wikidata
- Wikidata Q617563cysteamineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61696CysteamineOne source FDA
- DrugBank DB00847One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D003543 | Cysteamine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5UX2SD1KE2 | CYSTEAMINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3022 | — | Confirmed FDA, Wikidata |
| Wikidata | Q617563 | cysteamine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61696 | Cysteamine | One source FDA |
| DrugBank | DB00847 | — | One source Wikidata |
Also registered as cysteamine bitartrate (UNII QO84GZ3TST · RxNorm 81990) and cysteamine hydrochloride (UNII IF1B771SVB · RxNorm 1426886).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.